Photodynamic therapy: A new approach to prostate cancer

被引：29
作者：
Rolf Muschter
机构：
[1] Diakoniekrankenhaus Academic Teaching Hospital, Rotenburg
来源：
Current Urology Reports | 2003年 / 4卷 / 3期
关键词：
Hypericin; mTHPC; Photodynamic Therapy; Photofrin; Prostate Cancer;
D O I：
10.1007/s11934-003-0073-4
中图分类号：
学科分类号：
摘要：
Photodynamic therapy (PDT) is based on the concept that light irradiation can change an inert substance into an active one. In urology, hematoporphyrin derivative (HpD) and Photofrin (Axcan Scandipharm Inc., Birmingham, AL) are used most commonly as photosensitizing agents predominantly for the treatment of transitional cell carcinoma of the bladder. To investigate the basics for PDT of prostate cancer, several studies were performed on the optical characteristics of prostate tissue and prostate carcinoma tissue in vitro and in vivo and on the penetration depths of different laser wavelengths. Initial experimental studies to treat prostate cancer with PDT using HpD were done on Dunning tumors in rats. Combined with interstitial applicators, photodynamic therapy seems to have a great potential in the treatment of prostate carcinoma. However, it is an experimental treatment and even a preliminary evaluation will be possible only after the conclusion of clinical studies with the corresponding long-term results. © 2003, Current Science Inc.
引用
收藏
页码：221 / 228
页数：7
相关论文
共 51 条
  • [1] Kelly J.F., Snell M.E., Berenbaum M.C., Photodynamic destruction of human bladder carcinoma, Br J Cancer, 31, pp. 237-244, (1975)
  • [2] Benson C.C., Farrow G.M., Kinsey J.H., Et al., Detection and localization of in situ carcinoma of the bladder with hematoporphyrin derivative, Mayo Clin Proc, 57, pp. 548-555, (1982)
  • [3] Benson R.C., Integral photoradiation therapy of multifocal bladder tumor, Eur Urol, 12, pp. 47-53, (1986)
  • [4] Nseyo U.O., Dougherty T.J., Sullivan L., Photodynamic therapy in the management of resistant lower urinary tract carcinoma, Cancer, 60, pp. 3113-3119, (1987)
  • [5] Shumaker B.P., Hetzel F.W., Clinical laser photodynamic therapy in the treatment of bladder carcinoma, Photochem Photobiol, 46, pp. 899-901, (1987)
  • [6] Benson R.C., Kinsey J.H., Cortese D.A., Et al., Treatment of transitional cell carcinoma of the bladder with hematoporphyrin derivative phototherapy, J Urol, 130, pp. 1090-1095, (1983)
  • [7] Jocham D., Baumgartner R., Stepp H., Unsold E., Clinical experience with the integral photodynamic therapy of bladder carcinoma, Photochem Photobiol, 6, pp. 183-187, (1990)
  • [8] Kriegmair M., Waidelich R., Lumper W., Et al., Integral photodynamic treatment of refractory superficial bladder cancer, J Urol, 154, pp. 1339-1341, (1995)
  • [9] Waidelich R., Stepp H., Baumgartner R., Et al., Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer, J Urol, 165, pp. 1904-1907, (2001)
  • [10] Kriegmair M., Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid, Urology, 44, pp. 836-840, (1994)
123456